New cancer drug safety test halted after early phase

NCT ID NCT05859464

Terminated Disease control Sponsor: Zai Lab (Hong Kong), Ltd. Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety of a new cancer drug called ZL-1218, both alone and combined with an existing immunotherapy. It involved 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find safe dosage levels and understand how the drug behaves in the body, but the trial was terminated early.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Zai Lab Site 1001

Shanghai, 200123, China
Zai Lab Site 1002

Hangzhou, 310009, China
Zai Lab Site 2001

Hackensack, New Jersey, 07601, United States
Zai Lab Site 2002

New York, New York, 10029, United States
Zai Lab Site 2003

Spokane, Washington, 99208, United States
Zai Lab Site 2005

Irvine, California, 92618, United States
Zai Lab Site 2007

Detroit, Michigan, 48201, United States
Zai Lab Site 8001

Barcelona, Barcelona, 8035, Spain
Zai Lab Site 8002

Valencia, Valencia, 46009, Spain
Zai Lab Site 8003

Seville, Sevilla, 41009, Spain
Zai Lab Site 8004

Pozuelo de Alarcón, Madrid, 28223, Spain
Zai Lab Site 8005

Barcelona, Barcelona, 8023, Spain
Zai Lab Site 8006

Valencia, Valencia, 46010, Spain
Zai Lab Site 8007

Madrid, Madrid, 28040, Spain
Zai Lab Site 8008

Madrid, Madrid, 28050, Spain

Conditions

Explore the condition pages connected to this study.

MALIGNANT SOLID TUMOR